Enhancing management of tuberculosis treatment with video directly observed therapy in New York City

Chuck, Christine; Robinson, Errol; Macaraig, Michelle; Alexander, Martha; Burzynski, Joseph

doi:10.5588/ijtld.15.0738

Cited by 108 publications

(144 citation statements)

References 11 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…A NYC study found VDOT to be a feasible alternative to in-person DOT while improving treatment adherence and maximizing health department resources. [15] However, only one published study known to the authors date have reported using VDOT to monitor patients on treatment for LTBI.…”

Section: [4] An Important Component Of the Us Centers For Diseasementioning

confidence: 99%

“…[8,15] Staff experienced with the two initiatives were consulted to inform the implementation plan, and the few technological issues encountered were easily resolved because staff experienced in using the software for [19], and providing additional software options may continue to make supervision of treatment more convenient for patients.…”

Section: Strengths and Limitationsmentioning

confidence: 99%

“…These programs have reported better or equal rates of treatment completion compared to in-person DOT while providing a more convenient and flexible option for patients. [2,[12][13][14][15] VDOT uses videoconferencing software to allow patients and staff to communicate remotely via smartphones, tablets, or desktop computers. A NYC study found VDOT to be a feasible alternative to in-person DOT while improving treatment adherence and maximizing health department resources.…”

Section: [4] An Important Component Of the Us Centers For Diseasementioning

confidence: 99%

“…[8,15] One worker with previous in-person DOT experience and two backup staff were trained to perform the observations for V3HP and in use of the videoconferencing software. To evaluate the V3HP pilot, program staff were trained in documentation procedures for monitoring patients in the pilot.…”

Section: Integration Of Video Directly Observed Therapy For Treatmentmentioning

confidence: 99%

“…Eligible patients treated for LTBI with 3HP between February and October 2015 at any of the four NYC Health Department TB clinics and who met NYC DOHMH eligibility requirements for VDOT [15] were offered participation in V3HP. Eligibility for V3HP included possession of a smartphone, tablet, or computer with videoconferencing capability, willingness to use their personal device for VDOT sessions, access to a reliable internet connection, and agreement to a VDOT schedule.…”

Section: Study Populationmentioning

confidence: 99%

See 4 more Smart Citations

Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study (Preprint)

Lam¹,

Pilote²,

Haque³

et al. 2018

Preprint

View full text Add to dashboard Cite

BACKGROUND Since January 2013, the New York City (NYC) Health Department Tuberculosis (TB) Program has offered persons diagnosed with latent TB infection (LTBI) the 3-month, once-weekly isoniazid and rifapentine (3HP) treatment regimen. Patients on this treatment are monitored in-person under directly observed therapy (DOT). To address patient and provider barriers to in-person DOT, we piloted the use of a videoconferencing software app to remotely conduct synchronous DOT (video directly observed therapy; VDOT) for patients on 3HP. OBJECTIVE The objective of our study was to evaluate the implementation of VDOT for patients on 3HP and to assess whether treatment completion for these patients increased when they were monitored using VDOT compared with that using the standard in-person DOT. METHODS Between February and October 2015, patients diagnosed with LTBI at any of the four NYC Health Department TB clinics who met eligibility criteria for treatment with 3HP under VDOT (V3HP) were followed until 16 weeks after treatment initiation, with treatment completion defined as ingestion of 11 doses within 16 weeks. Treatment completion of patients on V3HP was compared with that of patients on 3HP under clinic-based, in-person DOT who were part of a prior study in 2013. Furthermore, outcomes of video sessions with V3HP patients were collected and analyzed. RESULTS During the study period, 70% (50/71) of eligible patients were placed on V3HP. Treatment completion among V3HP patients was 88% (44/50) compared with 64.9% (196/302) among 3HP patients on clinic DOT (P<.001). A total of 360 video sessions were conducted for V3HP patients with a median of 8 (range: 1-11) sessions per patient and a median time of 4 (range: 1-59) minutes per session. Adherence issues (eg, >15 minutes late) during video sessions occurred 104 times. No major side effects were reported by V3HP patients. CONCLUSIONS The NYC TB program observed higher treatment completion with VDOT than that previously seen with clinic DOT among patients on 3HP. Expanding the use of VDOT may improve treatment completion and corresponding outcomes for patients with LTBI.

show abstract

Section: [4] An Important Component Of the Us Centers For Diseasementioning

confidence: 99%